Complications after CyPass® Micro-Stent explantation: a case series

Int Ophthalmol. 2024 Feb 9;44(1):45. doi: 10.1007/s10792-024-02993-2.

Abstract

Purpose: To describe the in toto explantation of the CyPass® Micro-Stent and its conceivable complications.

Methods: This is a case series of eighteen eyes from fourteen patients who underwent CyPass® Micro-Stent implantation due to mild to moderate glaucoma and who subsequently suffered from loss of endothelial cell density. Consequently, the CyPass® Micro-Stent was in toto explanted. The surgical procedure and its complications are described and compared with trimming of the CyPass® Micro-Stent.

Results: A postoperative hyphema was developed in 8 of the 18 eyes. In four of them the hyphema was self-limiting, while in two patients an anterior chamber irrigation was necessary. One patient suffered from a severe intracameral bleeding and iridodialysis during explantation, so that the base of the iris had to be scleral fixated. The remaining explantations were without complications.

Conclusion: Dealing with implanted CyPass® Micro-Stents poses a challenge for ophthalmic surgeons. An in toto removal can be traumatic, since the CyPass stent often is fibrotic encapsulated and fused with the surrounding tissue. Alternatively, trimming of the CyPass is also a viable option to avoid further endothelial damage. Reported complications of CyPass trimming are consistent with those that can occur after explantation. Further data on the development of the endothelial cells after trimming or explantation are not yet available. Therefore, it remains open whether trimming of the CyPass, in contrast to complete removal, carries the risk of further endothelial cell loss.

Keywords: CyPass Micro-Stent explantation; CyPass trimming; Iridodialysis; Loss of endothelial cell density.

MeSH terms

  • Anterior Chamber
  • Endothelial Cells
  • Glaucoma Drainage Implants* / adverse effects
  • Glaucoma, Open-Angle* / surgery
  • Humans
  • Hyphema
  • Intraocular Pressure
  • Postoperative Complications
  • Quinolinium Compounds*
  • Stents / adverse effects
  • Thiazoles*

Substances

  • 1,1'-(4,4,7,7-tetramethyl-4,7-diazaundecamethylene)bis-4-(3-methyl-2,3-dihydro(benzo-1,3-thiazole)-2-methylidene)quinolinium
  • Quinolinium Compounds
  • Thiazoles